Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Salbutamol pMDI, Advisory Letter | 12/08/2025 |  |
| Important safety information on Non-steroidal anti-inflammatory drugs (NSAlDs) in Congo | 11/06/2021 | |
| Important safety information on Resorcinol in Congo | 23/02/2022 |  |
| Important safety information on Paroxetine in Congo (Safety Notification_EMA communication issued relating to Paroxetine label update) | 27-10-2023 | |
| Important safety information on Cefuroxime sodium in Congo (Safety Notification_Cefuroxime Class 4 Defect MHRA) | 30-10-2023 | |
| Important safety information on Topical Corticosteroids containing products in Congo | 15-11-2023 | |
Important safety information on Zanamivir containing products - Precautions for prescribing and administering flu medications (zanamivir) |
29/12/2023 |
|
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain Paroxetine |
28/12/2023 |
|
